文献速递胃肠动力与功能性疾病

利福昔明与低FODMAP饮食对IBS症状及菌群影响的随机试验

A Randomized Trial of Rifaximin vs Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-04-21

两者均显著改善腹痛、腹胀和IBS症状严重度评分(均P<.0001),但应答者的基线菌群特征不同。

要点

  • LFD与利福昔明对IBS-D症状改善效果相当,均显著优于基线。
  • LFD应答者基线产糖菌属较低,利福昔明应答者富产短链脂肪酸菌属。
  • 基线菌群特征或可预测治疗应答,但需验证后用于个体化治疗。

核心结论

  • LFD与利福昔明对IBS-D疗效相当,且各有不同的菌群预测因子。

主要发现

  • LFD与利福昔明均显著改善腹痛(LFD -0.29 vs 利福昔明 -0.24分/周)、腹胀(-0.29 vs -0.19分/周)和IBS症状严重度评分(-14.2 vs -13.3分/周),均P<.0001。
  • Bristol粪便性状量表无显著变化。
  • 基线氢呼气试验阳性与利福昔明应答几率降低相关,第5周甲烷转化与利福昔明应答呈不一致关联。
  • LFD应答者基线丁酸单胞菌属、拟杆菌属、肠杆菌属丰度较低;利福昔明应答者富集瘤胃球菌属、粪球菌属、臭杆菌属;无应答者富集嗜胆菌属、Alistipes、普雷沃菌属。

关键数值与推荐

  • 主要终点为第5周 vs 基线每日平均腹痛和腹胀变化。
  • 探索性应答定义为腹痛或腹胀减少≥30%。

临床怎么用

  • LFD和利福昔明均可作为IBS-D的有效治疗选择。
  • 基线菌群特征有望指导治疗选择,但当前证据尚不足以用于临床个性化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet (LFD) and rifaximin are effective in <50% individuals with irritable bowel syndrome (IBS), highlighting the need to identify predictors of treatment response. We therefore conducted a randomized controlled trial comparing LFD and rifaximin to identify microbial predictors of response. METHODS: Sixty-five adults with diarrhea-predominant IBS (IBS-D) were randomized to LFD or rifaximin for 5 weeks. Primary endpoints were changes in mean daily abdominal pain and bloating at week 5 vs baseline. Secondary endpoints included changes in IBS Symptom Severity Score and Bristol Stool Form Scale at week 5 vs baseline. Exploratory endpoints included responders defined as ≥30% reduction in abdominal pain or bloating. Stool samples collected at weeks 0, 2, 4, and 5 underwent 16S rRNA sequencing, and glucose breath testing (BT) was performed at weeks 0 and 5. RESULTS: Both LFD and rifaximin significantly improved abdominal pain (-0.29 with LFD vs -0.24 points/week with rifaximin); bloating (-0.29 vs -0.19 per week); and IBS Symptom Severity Score (-14.2 vs -13.3 per week) at week 5 (all P < .0001), with no significant change in Bristol Stool Form Scale. BT results were inconsistent predictors of response, with positive baseline hydrogen BT associated with lower odds of rifaximin response, and methane conversion at week 5 showed discordant associations with rifaximin response. In contrast, distinct baseline taxa were associated with treatment response. LFD responders had lower abundance of putative saccharolytic taxa (Butyricimonas, Bacteroides, Intestinibacter), whereas rifaximin responders were enriched in taxa with putative short-chain fatty acid-producing and bile acid-modifying potential (Ruminococcus, Coprococcus, Odoribacter). Nonresponders exhibited enrichment of putative proteolytic taxa (Bilophila, Alistipes, Prevotella). CONCLUSIONS: LFD and rifaximin are equally effective for IBS-D, with distinct microbial predictors of response. However, these findings require validation before informing personalized treatment approaches. CLINICALTRIALS: gov, Number: NCT03219528.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lee AA, Rao K, Singh P, et al. A Randomized Trial of Rifaximin vs Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2026. PMID: 42025708. doi:10.1016/j.cgh.2026.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。